Close Menu

You may find more results for this query on our sister sites: GenomeWeb and Precision Oncology News.

Home › FDA Approves Expanded Use of Agilent CDx for Keytruda in Head and Neck Cancer

FDA Approves Expanded Use of Agilent CDx for Keytruda in Head and Neck Cancer

Jun 11, 2019
|
staff reporter

NEW YORK (360Dx) – Agilent Technologies announced on Tuesday that the US Food and Drug Administration has expanded its approval of the firm's Dako PD-L1 IHC 22C3 pharmDx assay as a companion diagnostic test for Merck's anti-PDL-1 immunotherapy pembrolizumab (Keytruda) for head and neck squamous cell carcinoma (HNSCC).

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

What's Popular?

In Regulatory News & FDA Approvals

  1. Abbott POC Coronavirus Test Snares FDA Emergency Use Authorization

  2. SARS-CoV-2 Serology Testing Ramping Up to Address Next Stages of Pandemic

  3. Luminex Receives FDA Emergency Use Authorization for Coronavirus Multiplex Panel

  4. BioMérieux Rapid Coronavirus Test Gets FDA Emergency Use Authorization

  5. Thermo Fisher Scientific COVID-19 Test Receives CE Mark, Expanded FDA EUA

Sponsorships

Privacy Policy.  Terms & Conditions.  .  Copyright © 2020 GenomeWeb, a business unit of Crain Communications.  All Rights Reserved.